AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (March 2022)

47 slides from AVEO Pharmaceuticals's investor presentation, Mar 14, 2022

  1. Slide 1: Corporate Overview March 2022

    Passionately pursuing a better life for patients with cancer Corporate Overview March 2022

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

  3. Slide 3: Recent Highlights

    3 Recent Highlights Commercial • Successfully built and deployed FOTIVDA launch team • Quarter over quarter revenue and TRx growth despite COVID-19 physician access challenges • Achieved $38.9M in 2021 US net product revenue with three full quarters of commercial launch Financial/Corporate • $58.2M

  4. Slide 4: Oncology Company With Pipeline to Drive Long-term Growth

    Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner VEGFR TKI Ficlatuzumab Anti-HGF/c-MET IgG1 mAb AV-380 Anti-GDF15 IgG1 mAb AV-203 Anti-ERBB3 IgG1 mAb AV-353 Anti-Notch 3 IgG1 mAb Oncology Company With Pipeline to Drive Long-term Growth Ex-US (RCC 1st line) US (RCC following two

  5. Slide 5: Oncology

    ONCOLOGY ()FOTIVDA M/=O (tivozanio) capsules

  6. Slide 6: FOTIVDA (tivozanib)

    Full prescribing information available at www.FOTIVDA.com FOTIVDA® (tivozanib) FOTIVDA (tivozanib) is an oral, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (

  7. Slide 7: FOTIVDA: A Uniquely Positioned VEGF-TKI

    FOTIVDA: A Uniquely Positioned VEGF-TKI • Potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities • TIVO-3: Superior disease control (PFS, ORR & DoR) vs. sorafenib • Fewer dose reductions, interruptions

  8. Slide 8: ASCO GU 2022 – Five Year Efficacy Update

    8 ASCO GU 2022 – 5 Year Efficacy Update 3 Year 12% vs 2% 4 Year 8% vs 0% Five year follow-up data show FOTIVDA® (tivozanib) patients were up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease

  9. Slide 9: Significant Unmet Need In R/R Advanced RCC

    Significant Unmet Need In R/R Advanced RCC1 Limited data exists for the treatment of highly refractory RCC patients and following immunotherapy Existing treatment options have tolerability challenges requiring frequent dose modifications Only about 50% of patients who received second-line treatment

  10. Slide 10: IMDC Database: Third-line Treatment Demonstrated to Improve Survival

    0.00 0.25 0.50 0.75 1.00 0 20 40 60 80 100 IMDC Database: Third-line Treatment Demonstrated to Improve Survival ~2X vs. No Therapy1 10 ** 1 Wells JC, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consort

  11. Slide 11: US RCC Market by Line of Therapy

    US RCC Market by Line of Therapy 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 1st Line 2nd Line 3rd Line+ Annual Incidence of RCC Patients by Line of Therapy1 Treated Un-Treated 1) Decision Resources Group (DRG) projections 2022 (Nov. 2021 Market Update) • 10,000 patients make it to

  12. Slide 12: FOTIVDA Net Revenue by Quarter

    FOTIVDA Net Revenue by Quarter $1.1 $6.7 $14.3 $16.8 Q1 '21* Q2 '21 Q3 '21 Q4 '21 (I n M il li o n s ) Q4 ‘21 Notes • 17% growth in Net Revenue from Q3 to Q4 • $38.9M in Net Revenue YTD *Commercial Availability Commenced on March 22, 2021 (1 Week of Sales in Q1 21) 12

  13. Slide 13: Quarter over Quarter Prescription Growth

    283 619 780 Q1 '21* Q2 '21 Q3 '21 Q4 '21 TRxs Quarter over Quarter Prescription Growth Q4 ‘21 Notes • 26% growth in TRxs quarter over quarter • Over 330 accounts have ordered since launch • Ordering accounts represent over 1/3 of RCC market potential *Commercial Availability Commenced on March 22, 2

  14. Slide 14: Achieving Leadership Position in 3rd Line RCC

    Achieving Leadership Position in 3rd Line RCC *IQVIA Brand Impact Report January 2022 – New Patient Share (NPS) and Total Patient Share (TPS) • Initial utilization largely in late line patients (4th line+) • Team focused on delivering positive initial experience to lead to broader adoption • As of D

  15. Slide 15: Earlier Line Patients Have Fewer Early Discontinuations

    Earlier Line Patients Have Fewer Early Discontinuations • Post FOTIVDA FDA approval, the majority of initial FOTIVDA utilization was in late-stage patients (4th line and beyond) • We are seeing increasing patient starts in the earlier 3rd line setting starting in Q4 • The rate of early discontinuati

  16. Slide 16: Strategic Objectives for 2022

    Strategic Objectives for 2022 Educate and Raise Awareness • Leading share of voice in R/R RCC • Increase in-person activity where possible • Expand non-personal promotional tactics to reach accounts closed to industry due to COVID restrictions Broaden Base of Prescribers • Continue to expand our bas

  17. Slide 17: Focused Oncology Team with Broad Market Coverage

    Focused Oncology Team with Broad Market Coverage • Experienced oncology field force for effective market coverage (~65 FTEs) • Commercial Team designed for success through evolving COVID restrictions • Full in-person and remote customer engage capabilities • Multi-channel promotional initiatives • A

  18. Slide 18: FOTIVDA Available Through Limited Network of Specialty Pharmacies

    FOTIVDA® (tivozanib) Is Available Through a Limited Network of Specialty Pharmacies and Distributors Specialty Pharmacies (US) Biologics Onco360 Specialty Distributors (US) – Hospitals ASD Specialty Healthcare Cardinal Health Specialty Distribution McKesson Plasma & Biologics Specialty Distributors

  19. Slide 19: Providing Best-in-Class Patient Support: The AVEO ACE Program

    Affordability AdherenceAccess START on Therapy STAY on Therapy QuickStart / Bridge Program Benefits Investigation Prior Authorization Support Denials / Appeals Support Copay Card Program Patient Assistance Program Alternative Funding Research Nurse Support Calls Patient / Caregiver Education Program

  20. Slide 20: Building Toward Sustainable Value Creation as an Integrated Commercial Company

    Building Toward Sustainable Value Creation as an Integrated Commercial Company 20

  21. Slide 21: Tivozanib Combination Opportunities

    Tivozanib Combination Opportunities

  22. Slide 22: Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy

    Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy 22 Tolerability is Important in Combinations Tivozanib Significantly Reduce

  23. Slide 23: Anti-tumor Activity Seen in Treatment Naive and Previously Treated RCC Patients

    Treatment Naïve (n=12) Pre-Treated (n=13) Includes 2 Prior CPI Pts Overall (n=25) CR 8% - 4% PR 42% 62% 52% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR* (11.0, NR) 18.9 mo (16.4, NR) Dose reductions 17% Nivolumab Mono2Tivozanib Mono1 ORR 18% PFS 11.0 ORR 25% PFS 4.6

  24. Slide 24: TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy

    TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare FOTIVDA® with OPDIVO® to FOTIVDA® Following Immunotherapy in RCC Patients N = 326 • Histologically / cytologically confirmed recurrent/metastatic RCC • ECOG PS 0 or

  25. Slide 25: 1st Line HCC VEGF Combination Comparison

    Regimen Study PS Status ECOG 0 ORR^ DCR PFS* 1 Year OS Rate Bev+Atezo1, 2 Ph3 N=501 (2:1) 62% 28% 74% 6.8m 67% Cabo+Atezo3 Ph3 N=372 (2:1) 64% 11% 78% 5.8m N/A Tivo+Durva4 Ph2 N=18 40% 28% 72% 7.3m 76% References: 1USPI for Tecentriq; 2Verret, W. et al., Atezolizumab plus Bevacizumab in Unresectable

  26. Slide 26: Clinical Trial Collaboration: Tivozanib and NKT2152

    Clinical Trial Collaboration: Tivozanib and NKT2152 • AVEO and NiKang entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang’s small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with tivozanib • Sixty patient Phase 2 clinical trial

  27. Slide 27: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

    Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

  28. Slide 28: Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC

    Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC 28 Source: Zhang Y, Jain R and Zhu M. Biomedicines, 2015 (Zhang Y, Jain RK, and Zhu M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines. 2015; 3, 149-181 d

  29. Slide 29: Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC

    Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC Update • Granted U.S. FDA Fast Track Designation for the treatment of patients with R/R HNSCC • Initiated manufacturing scale up of clinical supply and expected to complete drug substance manufacturing run in 2Q 2022 • Potential regis

  30. Slide 30: Financials and Near-Term Milestones

    Financials and Near-Term Milestones

  31. Slide 31: Financial Snapshot as of Dec. 31, 2021

    31 Cash as of Dec. 31, 2021 $87.3M Revenue FY 2021 $42.3M Debt as of Dec. 31, 2021 $38.0M Shares Outstanding as of Dec 31, 2021 34.5M 4Q 2021 FY 2021 Cash Burn from Operations ($12.0M) ($58.0M) AVEO believes that its current cash, cash equivalents and marketable securities, along with expected net p

  32. Slide 32: Key Recent and Potential Milestones

    Key Recent and Potential Milestones AV-380 (Anti-GDF15 IgG1 mAb) 2021 1H 22 2H 22 Initiate Phase 1b Trial in Cancer Patients Ficlatuzumab (Anti-HGF/c-MET IgG1 mAb) 2021 1H 22 2H 22 HNSCC Randomized (Ficlatuzumab +/- Cetuximab) Phase 2 Data Presentation (ASCO) Granted U.S. FDA Fast Track Designation

  33. Slide 33: Thank you

    Passionately pursuing a better life for patients with cancer Thank you

  34. Slide 34: Appendix

    Appendix A/=O ONCOLOGY

  35. Slide 35: FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI

    FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life designed to improve efficacy and tolerability 35 Pawlowski N et al. AACR 2013. Poster 3971. • Cabozantinib and lenvatinib are not shown because absolute oral bioavailabilities are no

  36. Slide 36: TIVO-3: Pivotal Trial in RCC

    : Pivotal Trial in RCC Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With R/R Advanced RCC Results published in Lancet Oncology in December 2019 N = 350 • Histologically / cytologically confirmed recurrent/metastatic RCC • ECOG PS 0 or

  37. Slide 37: TIVO-3: First Positive Phase 3 Dataset in Adult Patients

    : First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies Source: PFS final analysis, Oct 4, 2018, U.S. FOTIVDA® Package Insert37 TIVO-3 Primary Endpoint: PFS of Tivozanib vs. Sorafenib Secondary Endpoints: ORR, DCR, DoR, OS Treatment Group Tivozanib n=175 Sor

  38. Slide 38: TIVO-3: Exploratory Analysis of Pre-Defined Subgroups

    : Exploratory Analysis of Pre-Defined Subgroups: Prior Checkpoint Inhibitor and TKI/TKI 38 Porta et al. ASCO 2019 Other + VEGFR TKI: (N=100) HR=0.98; 95% CI 0.62; 1.56, ASCO GI 2019 0 20 40 60 80 100 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 P ro g re s s io n -f re e S u rv iv a l (% ) 0 20 40 60

  39. Slide 39: TIVO-3: Safety & Tolerability

    *Analysis as of Aug 15, 2019; ^Safety population **Includes fatigue and asthenia; † Includes hypertension, blood pressure increased, hypertensive crisis; § Includes diarrhea and frequent bowel movements.; # Includes dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema

  40. Slide 40: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

    Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

  41. Slide 41: Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative HNSCC

    41 Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative Pan-Refractory, Metastatic HNSCC HPV negative HNSCC is historically associated with poorer outcomes compared to HPV positive disease F (=26) F+C (n=32) HPV+ ORRa 0/10 (0%) 0/16 (0%)d mPFSb NEc 2.3 (1.9)e HPV- ORRa 1PR/16 (6%) 2CR + 4PR

  42. Slide 42: Efficacy Benchmarks: Low Response Rates and Limited PFS in R/M HNSCC

    1ERBITUX (cetuximab) USPI November 2020, Eli Lilly and Company, Indianapolis, IN. 2OPDIVO (nivolumab) USPI January 2021, Bristol Myers Squibb, Princeton, NJ., 3http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm. Updated November 10, 2016. Accessed November 10, 2016. 4Combination

  43. Slide 43: Significant Unmet Need Exists for HPV Negative HNSCC

    Significant Unmet Need Exists for HPV Negative HNSCC1 43 1 Galvis et al, Critical Reviews in Oncology/Hematology 15 (2020) 102966

  44. Slide 44: Ficlatuzumab: Phase 2 Randomized Study in Pan-Refractory, Metastatic HNSCC

    Ficlatuzumab: Phase 2 Randomized Study in Pan- Refractory, Metastatic HNSCC Patients Randomized, confirmatory Phase 2 study in combination with cetuximab, an EGFR-targeted antibody, patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab with metastatic HNSCC N =

  45. Slide 45: Additional Pipeline Programs

    Additional Pipeline Programs

  46. Slide 46: AV-380: GDF15 Role in Cachexia

    AV-380: GDF15 Role in Cachexia 46 * J. Cachexia, Sarcopenia and Muscle 2010 + AVEO data on file Cachexia is a muscle wasting disease commonly associated with cancer • ~50% of people with cancer will suffer from cachexia* • ~30% of all cancer patients die from cachexia* GDF15 is a key driver in cance

  47. Slide 47: AV-203: A potent humanized IgG1 mAb that targets ErbB3

    AV-203: A potent humanized IgG1 mAb that targets ErbB3 • Humanized IgG1 antibody – Low risk of ADA response and hypersensitivity – Potential for inducing ADCC • Potent inhibitor of NRG/HRG - dependent and independent ERBB3 activation • Higher ERBB3 affinity and more potent anti-tumor activity than c

AVEO Pharmaceuticals — Investor Presentation (March 2022) on 6ix